Document is current
Any future updates will be listed below
-
Authors
Simitsi, Athina Maria https://orcid.org/0000-0002-7130-6256
Sfikas, Evangelos
Koros, Christos
Papagiannakis, Nikolaos
Beratis, Ion
Papadimitriou, Dimitra
Antonellou, Roubina
Fragiadaki, Styliani
Kontaxopoulou, Dionysia
Picillo, Marina
Pachi, Ioanna
Alefanti, Ioanna
Stamelou, Maria
Barone, Paolo
Stefanis, Leonidas
-
Funding
Funding for this research was provided by:
Michael J. Fox Foundation for Parkinson's Research
- License Information
-
More Information
Article History
Received: 11 November 2024
Accepted: 25 November 2024
First Online: 12 February 2025
Declarations
: The author(s) would like to disclose the following: Athina Maria Simitsi received funding from the Michael J Fox Foundation for her participation in PPMI; Evangelos Sfikas has no disclosures; Christos Koros received funding from the Michael J Fox Foundation for his participation in PPMI; Nikolaos Papagiannakis received funding from the Michael J Fox Foundation for his participation in PPMI; Ion Beratis received funding from the Michael J Fox Foundation for his participation in PPMI; Dimitra Papadimitriou has no disclosures; Roubina Antonelou received funding from by the National Network for Research of Neurodegenerative Diseases on the basis of Medical Precision (Grant 2018E01300001), funded by the General Secretariat of Research and Innovation (GSRI), and by Brain Precision(TAEDR-0535850), funded by the GSRI, through funds provided by the European Union (Next Generation EU)to the National Recovery and Resilience Plan; Stella Fragkiadaki received funding from the Michael J Fox Foundation for her participation in PPMI; Dionysia Kontaxopoulou received funding from the Michael J Fox Foundation for her participation in PPMI; Marina Picillo received funding from the Italian Ministry of Health, the Italian Ministry of University and Fondazione della Società Italiana di Neurologia; Ioanna Pachi has no disclosures; Ioanna Alefanti has no disclosures; Maria Stamelou has no disclosures; Paolo Barone Prof Paolo Barone received consultancies as a member of the advisory board for Zambon, Lundbeck, UCB, Chiesi, Abbvie and Acorda; Leonidas Stefanis over the past year has received the following grants: PPMI2(supported by the Michael J. Fox Foundation), IMPRIND-IMI2 Number 116060 (EU, H2020), "Transferring autonomous and non-autonomous cell degeneration 3D models between EU and USA for development of effective therapies for neurodegenerative diseases (ND)—CROSS NEUROD" (H2020-EU 1.3.3., GrantNumber778003), «Chaperone-Mediated Autophagy in Neurodegeneration» (Hellenic Foundation for Research and Innovation Grant HFRI-FM17-3013), "ALAMEDA" (H2020-EU, Grant Agreement 101017558),"Next-generation antisense molecules for Parkinson's disease therapy (THERASYN)" (Greek Secretariat of Research and Technology (GSRT), Collaborator), "Brain Precision" (GSRT), and "CMA as a Means to Counteract alpha-Synuclein Pathology in Non-Human Primates" (by the Michael J. Fox Foundation(Collaborator)). He has served on Advisory Boards for Abbvie, Innovis Pharma, ITF Hellas and Biogen and has received honoraria from ITF Hellas, Innovis Pharma and Abbvie.
